Abstract
Amyotrophic lateral sclerosis (ALS) is an incurable disease resulting from the deterioration of motor neurons. The onset of disease typically occurs in the fifth decade of life and progresses rapidly; death occurs for 75% of patients within 5 years. The only drug that is available to treat ALS is riluzole, which extends survival by just 2-3 months. Thus, new therapeutic directions are being sought to prolong the lifespan of ALS patients. Since the discovery of SOD1 as a genetic determinant of ALS in 1993, SOD1-models of ALS have been extensively employed for the development of ALS therapeutics. Novel genetic targets are now under investigation following the recent discoveries linking TDP-43, FUS/TLS, angiogenin, KIFAP3 and UNC13A to ALS. In this review, we present several of the genetic contributors to both sporadic and familial forms of ALS and discuss their potential as therapeutic targets for this devastating disease.
Keywords: Amyotrophic lateral sclerosis, neurodegeneration, therapy, genome-wide association, SOD1, TDP-43, FUS/TLS, angiogenin, KIFAP3, UNC13A, familial ALS, Alzheimer's disease, Parkinson's disease, Huntington's disease, immunotherapy, FALS, chaperones, arimoclomol, TAR, SALS, frontotemporal lobar degeneration, (GWAS), DPP6
CNS & Neurological Disorders - Drug Targets
Title: Genetic Determinants of Amyotrophic Lateral Sclerosis as Therapeutic Targets
Volume: 9 Issue: 6
Author(s): Daryl A. Bosco and John E. Landers
Affiliation:
Keywords: Amyotrophic lateral sclerosis, neurodegeneration, therapy, genome-wide association, SOD1, TDP-43, FUS/TLS, angiogenin, KIFAP3, UNC13A, familial ALS, Alzheimer's disease, Parkinson's disease, Huntington's disease, immunotherapy, FALS, chaperones, arimoclomol, TAR, SALS, frontotemporal lobar degeneration, (GWAS), DPP6
Abstract: Amyotrophic lateral sclerosis (ALS) is an incurable disease resulting from the deterioration of motor neurons. The onset of disease typically occurs in the fifth decade of life and progresses rapidly; death occurs for 75% of patients within 5 years. The only drug that is available to treat ALS is riluzole, which extends survival by just 2-3 months. Thus, new therapeutic directions are being sought to prolong the lifespan of ALS patients. Since the discovery of SOD1 as a genetic determinant of ALS in 1993, SOD1-models of ALS have been extensively employed for the development of ALS therapeutics. Novel genetic targets are now under investigation following the recent discoveries linking TDP-43, FUS/TLS, angiogenin, KIFAP3 and UNC13A to ALS. In this review, we present several of the genetic contributors to both sporadic and familial forms of ALS and discuss their potential as therapeutic targets for this devastating disease.
Export Options
About this article
Cite this article as:
A. Bosco Daryl and E. Landers John, Genetic Determinants of Amyotrophic Lateral Sclerosis as Therapeutic Targets, CNS & Neurological Disorders - Drug Targets 2010; 9 (6) . https://dx.doi.org/10.2174/187152710793237494
DOI https://dx.doi.org/10.2174/187152710793237494 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Flavonoids as Sirtuin Modulators
Current Topics in Medicinal Chemistry A Glycation Angle to Look into the Diabetic Vasculopathy: Cause and Cure
Current Vascular Pharmacology Longevity Pathways (mTOR, SIRT, Insulin/IGF-1) as Key Modulatory Targets on Aging and Neurodegeneration
Current Topics in Medicinal Chemistry Glutaminase Isoenzymes as Key Regulators in Metabolic and Oxidative Stress Against Cancer
Current Molecular Medicine Editorial (Hot Topic: Regenerative Medicine in Neurological Diseases)
Recent Patents on Regenerative Medicine Creatine and the Liver: Metabolism and Possible Interactions
Mini-Reviews in Medicinal Chemistry Influence of Essential Trace Minerals and Micronutrient Insufficiencies on Harmful Metal Overload in a Mongolian Patient with Multiple Sclerosis
Current Aging Science Ultrasound-Induced Blood-Brain Barrier Opening
Current Pharmaceutical Biotechnology Ceftriaxone and Phenylalanine Combination as Broad Spectrum Antimicrobials Therapy
Current Drug Therapy The Bioanalytical Molecular Pharmacology of the N-methyl-<sub>D</sub>-Aspartate (NMDA) Receptor Nexus and the Oxygen-Responsive Transcription Factor HIF-1α : Putative Mechanisms and Regulatory Pathways Unravel the Intimate Hypoxia Connection
Current Molecular Pharmacology Integrating Qualitative and Quantitative Tools for the Detection and Identification of Lectins in Major Human Diseases
Protein & Peptide Letters Human Cognitive and Neuro-Psychiatric Bio-Markers in the Cardiac Peri-Operative Patient
Current Molecular Medicine Scientific Basis for the Use of Indian Ayurvedic Medicinal Plants in the Treatment of Neurodegenerative Disorders: 1. Ashwagandha
Central Nervous System Agents in Medicinal Chemistry Physically Cross-linked Hydrogels of β -cyclodextrin Polymer and Poly(ethylene glycol)-cholesterol as Delivery Systems for Macromolecules and Small Drug Molecules
Current Drug Delivery Antioxidant Activity of Galantamine and Some of its Derivatives
Current Medicinal Chemistry Importance of Zebrafish as an Efficient Research Model for the Screening of Novel Therapeutics in Neurological Disorders
CNS & Neurological Disorders - Drug Targets A Hypothesis for Regenerative Therapy for Neuronal Disease: Stem Cells within Artificial Niche
Current Signal Transduction Therapy Anti-neoplastic and Calcium modulatory action of Caffeic acid phenethyl ester and Dasatinib in C6 glial cells: A Therapeutic Perspective
CNS & Neurological Disorders - Drug Targets Therapeutic Effects of Progesterone in Animal Models of Neurological Disorders
CNS & Neurological Disorders - Drug Targets Translational Therapeutic Str ategies in Amyotrophic Lateral Sclerosis
Mini-Reviews in Medicinal Chemistry